Background Cervical cancer screening tests that identify DNA of the main causal agent, high-
risk human papillomavirus (HPV) types, are more protective than cervical cytology. We …

Despite HPV vaccines, screening will remain central for decades to control cervical cancer.
Recently, HPV testing alone or with cytology was introduced as an alternative to cytology …

Background Human papillomavirus (HPV) testing on self-samples represents a great
opportunity to increase cervical cancer screening uptake among under-screened women …

Infection of cervical epithelium with high-risk human papilloma virus (hrHPV) might result in
productive or transforming cervical intraepithelial neoplasia (CIN) lesions, the morphology of …

Background Cervical cancer screening has traditionally been based on cervical cytology.
Given the aetiological relationship between human papillomavirus (HPV) infection and …

Introduction Population coverage for cervical cancer screening is an important determinant
explaining differences in the incidence of cervical cancer between countries. Offering …

Objective To examine whether or not self-sampled cervical screening for human
papillomavirus (HPV) DNA is acceptable and if women prefer self-sampling to clinician …

The age‐standardised incidence of cervical cancer in Europe varies widely by country
(between 3 and 25/100000 women‐years) in 2018. Human papillomavirus (HPV) vaccine …

Several countries are in the process of switching to high-risk human papillomavirus (hrHPV)
testing for cervical cancer screening. Given the multitude of available tests, validated assays …

In a project coordinated by the International Agency for Research on Cancer (IARC) 31
experts from 11 European countries and IARC have developed supplements to the current …